RARE
Ultragenyx Pharmaceutical Inc.
Price Chart
Latest Quote
$27.44
+0.53 (+1.97%)
Current Price
| Previous Close | $26.91 |
| Open | $27.54 |
| Day High | $28.18 |
| Day Low | $27.31 |
| Volume | 3,562,450 |
Stock Information
| Shares Outstanding | 98.49M |
| Total Debt | $1.20B |
| Cash Equivalents | $413.00M |
| Revenue | $670.00M |
| Net Income | $-609.00M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.70B |
| EPS (TTM) | $-6.11 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.49B |
| Sales | $670.00M |
| Income | $-609.00M |
| Book/sh | $-2.41 |
| Cash/sh | $4.19 |
| Employees | 1K |
Financial Ratios
| Quick Ratio | 1.65 |
| Current Ratio | 2.02 |
Returns & Margins
| ROA | -25.45% |
| Gross Margin | -28.06% |
| Operating Margin | -102.21% |
| Profit Margin | -90.90% |
Ownership
| Insider Ownership | 3.46% |
| Institutional Ownership | 104.39% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 28.43 |
| P/S | 4.03 |
| P/B | -11.40 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $52.05 |
Technical Indicators
| SMA20 | $23.67 |
| SMA50 | $24.32 |
| SMA200 | $27.03 |
| RSI | 64.20 |
| ATR | 1.3450 |
| Shares Float | 94.50M |
| Short Float | 15.44% |
| Short Ratio | 8.89 |
| Volatility | 0.38 |
| Rel Volume | 1.98 |
Performance History
| Week | +14.43% |
| Month | +22.23% |
| Quarter | +34.38% |
| 6 Months | -20.09% |
| YTD | +16.27% |
| Year | -25.15% |
| 3 Years | -47.26% |
| 5 Years | -73.02% |
| 10 Years | -49.65% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $27.44 | 3,562,400 |
| 2026-06-17 | $26.91 | 3,243,000 |
| 2026-06-16 | $24.85 | 2,747,400 |
| 2026-06-15 | $25.38 | 1,479,200 |
| 2026-06-12 | $24.35 | 1,846,700 |
| 2026-06-11 | $23.98 | 1,527,200 |
| 2026-06-10 | $22.97 | 1,200,800 |
| 2026-06-09 | $22.79 | 1,622,600 |
| 2026-06-08 | $21.59 | 1,689,300 |
| 2026-06-05 | $21.91 | 1,117,000 |
| 2026-06-04 | $23.31 | 1,412,100 |
| 2026-06-03 | $22.41 | 1,799,400 |
| 2026-06-02 | $21.78 | 2,029,000 |
| 2026-06-01 | $22.85 | 2,328,000 |
| 2026-05-29 | $23.94 | 1,843,200 |
| 2026-05-28 | $23.26 | 1,258,000 |
| 2026-05-27 | $23.39 | 1,685,000 |
| 2026-05-26 | $23.14 | 1,219,400 |
| 2026-05-22 | $23.39 | 1,130,500 |
| 2026-05-21 | $23.71 | 1,272,100 |
| 2026-05-20 | $23.37 | 1,547,800 |
| 2026-05-19 | $22.45 | 2,121,400 |
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
đ° Latest News
Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip Stocks
Insider Monkey âĸ 2026-06-13T15:28:45Z
How The Ultragenyx Pharmaceutical (RARE) Investment Story Is Shifting With New Data And Street Views
Simply Wall St. âĸ 2026-06-06T17:06:21Z
Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE)
Insider Monkey âĸ 2026-06-05T15:55:50Z
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
Zacks âĸ 2026-06-04T15:30:26Z
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
Motley Fool âĸ 2026-05-30T17:56:01Z
Is Ultragenyx (RARE) Reaffirming 2026â2027 Guidance Enough To Offset Its Widening Losses?
Simply Wall St. âĸ 2026-05-11T04:22:53Z
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
Zacks âĸ 2026-05-06T16:00:00Z
Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-06T12:30:00Z
Ultragenyx Pharmaceutical Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-06T02:07:23Z
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks âĸ 2026-05-05T22:00:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $109,000,000 | $77,000,000 | $45,000,000 | $28,320,000 |
| Cost Of Revenue | $109,000,000 | $77,000,000 | $45,000,000 | $28,320,000 |
| Total Revenue | $673,000,000 | $560,000,000 | $434,000,000 | $363,329,000 |
| Operating Revenue | $673,000,000 | $560,000,000 | $434,000,000 | $363,329,000 |
| Expenses | ||||
| Interest Expense | $62,000,000 | $63,000,000 | $66,000,000 | $43,015,000 |
| Total Expenses | $1,208,000,000 | $1,096,000,000 | $1,003,000,000 | $1,012,248,000 |
| Other Income Expense | $1,000,000 | $-5,000,000 | $-1,000,000 | $-20,865,000 |
| Other Non Operating Income Expenses | $1,000,000 | $-5,000,000 | $-1,000,000 | $-1,566,000 |
| Net Non Operating Interest Income Expense | $-37,000,000 | $-26,000,000 | $-39,000,000 | $-31,941,000 |
| Interest Expense Non Operating | $62,000,000 | $63,000,000 | $66,000,000 | $43,015,000 |
| Operating Expense | $1,099,000,000 | $1,019,000,000 | $958,000,000 | $983,928,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-575,000,000 | $-569,000,000 | $-607,000,000 | $-707,421,000 |
| Net Interest Income | $-37,000,000 | $-26,000,000 | $-39,000,000 | $-31,941,000 |
| Interest Income | $25,000,000 | $37,000,000 | $27,000,000 | $11,074,000 |
| Normalized Income | $-575,000,000 | $-569,000,000 | $-607,000,000 | $-692,174,790 |
| Net Income From Continuing And Discontinued Operation | $-575,000,000 | $-569,000,000 | $-607,000,000 | $-707,421,000 |
| Total Operating Income As Reported | $-535,000,000 | $-536,000,000 | $-569,000,000 | $-648,919,000 |
| Net Income Common Stockholders | $-575,000,000 | $-569,000,000 | $-607,000,000 | $-707,421,000 |
| Net Income | $-575,000,000 | $-569,000,000 | $-607,000,000 | $-707,421,000 |
| Net Income Including Noncontrolling Interests | $-575,000,000 | $-569,000,000 | $-607,000,000 | $-707,421,000 |
| Net Income Continuous Operations | $-575,000,000 | $-569,000,000 | $-607,000,000 | $-707,421,000 |
| Pretax Income | $-571,000,000 | $-567,000,000 | $-609,000,000 | $-701,725,000 |
| Interest Income Non Operating | $25,000,000 | $37,000,000 | $27,000,000 | $11,074,000 |
| Operating Income | $-535,000,000 | $-536,000,000 | $-569,000,000 | $-648,919,000 |
| Gross Profit | $564,000,000 | $483,000,000 | $389,000,000 | $335,009,000 |
| Per Share | ||||
| Diluted EPS | $-5.83 | $-6.29 | $-8.25 | $-10.12 |
| Basic EPS | $-5.83 | $-6.29 | $-8.25 | $-10.12 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-4,052,790 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-474,000,000 | $-468,000,000 | $-517,000,000 | $-621,191,000 |
| Reconciled Depreciation | $35,000,000 | $36,000,000 | $26,000,000 | $18,220,000 |
| EBITDA (Bullshit earnings) | $-474,000,000 | $-468,000,000 | $-517,000,000 | $-640,490,000 |
| EBIT | $-509,000,000 | $-504,000,000 | $-543,000,000 | $-658,710,000 |
| Diluted Average Shares | $98,600,000 | $90,538,118 | $73,543,862 | $69,914,225 |
| Basic Average Shares | $98,600,000 | $90,538,118 | $73,543,862 | $69,914,225 |
| Diluted NI Availto Com Stockholders | $-575,000,000 | $-569,000,000 | $-607,000,000 | $-707,421,000 |
| Tax Provision | $4,000,000 | $2,000,000 | $-2,000,000 | $5,696,000 |
| Research And Development | $750,000,000 | $698,000,000 | $648,000,000 | $705,789,000 |
| Selling General And Administration | $349,000,000 | $321,000,000 | $310,000,000 | $278,139,000 |
| Total Unusual Items | - | $-1,115,000 | $397,000 | $-19,299,000 |
| Total Unusual Items Excluding Goodwill | - | $-1,115,000 | $397,000 | $-19,299,000 |
| Gain On Sale Of Security | - | $-1,115,000 | $397,000 | $-19,299,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-300,000,000 | $33,000,000 | $64,737,000 | $147,983,000 |
| Total Assets | $1,532,000,000 | $1,503,000,000 | $1,491,013,000 | $1,545,444,000 |
| Total Non Current Assets | $581,000,000 | $686,000,000 | $758,829,000 | $661,545,000 |
| Other Non Current Assets | $60,000,000 | $63,000,000 | $57,685,000 | $48,338,000 |
| Investmentin Financial Assets | $57,000,000 | $135,000,000 | $199,901,000 | $148,970,000 |
| Goodwill And Other Intangible Assets | $220,000,000 | $222,000,000 | $210,677,000 | $204,511,000 |
| Other Intangible Assets | $176,000,000 | $178,000,000 | $166,271,000 | $160,105,000 |
| Current Assets | $951,000,000 | $817,000,000 | $732,184,000 | $883,899,000 |
| Other Current Assets | $61,000,000 | $40,000,000 | $47,616,000 | $68,926,000 |
| Inventory | $52,000,000 | $45,000,000 | $33,969,000 | $26,766,000 |
| Receivables | $158,000,000 | $122,000,000 | $73,390,000 | $40,445,000 |
| Accounts Receivable | $158,000,000 | $122,000,000 | $73,390,000 | $40,445,000 |
| Cash Cash Equivalents And Short Term Investments | $680,000,000 | $610,000,000 | $577,209,000 | $747,762,000 |
| Cash And Cash Equivalents | $421,000,000 | $174,000,000 | $213,584,000 | $132,944,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $36,000,000 | $40,000,000 | $43,169,000 | $31,593,000 |
| Long Term Debt And Capital Lease Obligation | $24,000,000 | $30,000,000 | $30,574,000 | $19,814,000 |
| Current Debt And Capital Lease Obligation | $12,000,000 | $10,000,000 | $12,595,000 | $11,779,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,605,000,000 | $1,241,000,000 | $1,215,599,000 | $1,192,950,000 |
| Total Non Current Liabilities Net Minority Interest | $1,221,000,000 | $897,000,000 | $935,162,000 | $931,740,000 |
| Other Non Current Liabilities | $20,000,000 | $17,000,000 | $12,205,000 | $4,820,000 |
| Liabilities Heldfor Sale Non Current | $1,147,000,000 | $820,000,000 | $862,325,000 | $875,439,000 |
| Non Current Deferred Liabilities | $30,000,000 | $30,000,000 | $30,058,000 | $31,667,000 |
| Non Current Deferred Taxes Liabilities | $30,000,000 | $30,000,000 | $30,058,000 | $31,667,000 |
| Current Liabilities | $384,000,000 | $344,000,000 | $280,437,000 | $261,210,000 |
| Other Current Liabilities | $76,000,000 | $54,000,000 | $29,242,000 | - |
| Payables And Accrued Expenses | $239,000,000 | $247,000,000 | $221,571,000 | $247,952,000 |
| Payables | $31,000,000 | $39,000,000 | $42,114,000 | $43,274,000 |
| Accounts Payable | $31,000,000 | $39,000,000 | $42,114,000 | $43,274,000 |
| Current Deferred Liabilities | - | - | $0 | $1,479,000 |
| Equity | ||||
| Common Stock Equity | $-80,000,000 | $255,000,000 | $275,414,000 | $352,494,000 |
| Total Equity Gross Minority Interest | $-73,000,000 | $262,000,000 | $275,414,000 | $352,494,000 |
| Stockholders Equity | $-80,000,000 | $255,000,000 | $275,414,000 | $352,494,000 |
| Other Equity Interest | $8,000,000 | $4,000,000 | $432,000 | - |
| Gains Losses Not Affecting Retained Earnings | $1,000,000 | $-1,000,000 | $647,000 | $-6,573,000 |
| Other Equity Adjustments | $1,000,000 | $-1,000,000 | - | - |
| Retained Earnings | $-4,532,000,000 | $-3,957,000,000 | $-3,387,661,000 | $-2,781,022,000 |
| Long Term Equity Investment | - | - | - | $5,531,000 |
| Other | ||||
| Treasury Shares Number | $173,034 | $69,757 | $9,559 | - |
| Ordinary Shares Number | $96,477,569 | $92,484,330 | $82,315,590 | $70,197,297 |
| Share Issued | $96,650,603 | $92,554,087 | $82,325,149 | $70,197,297 |
| Tangible Book Value | $-300,000,000 | $33,000,000 | $64,737,000 | $147,983,000 |
| Invested Capital | $-80,000,000 | $255,000,000 | $275,414,000 | $352,494,000 |
| Working Capital | $567,000,000 | $473,000,000 | $451,747,000 | $622,689,000 |
| Capital Lease Obligations | $36,000,000 | $40,000,000 | $43,169,000 | $31,593,000 |
| Total Capitalization | $-80,000,000 | $255,000,000 | $275,414,000 | $352,494,000 |
| Minority Interest | $7,000,000 | $7,000,000 | $0 | - |
| Treasury Stock | $8,000,000 | $4,000,000 | $432,000 | $0 |
| Additional Paid In Capital | $4,451,000,000 | $4,213,000,000 | $3,662,346,000 | $3,140,019,000 |
| Capital Stock | $0 | $0 | $82,000 | $70,000 |
| Common Stock | $0 | $0 | $82,000 | $70,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $24,000,000 | $30,000,000 | $30,574,000 | $19,814,000 |
| Current Capital Lease Obligation | $12,000,000 | $10,000,000 | $12,595,000 | $11,779,000 |
| Current Provisions | $57,000,000 | $33,000,000 | $17,029,000 | - |
| Current Accrued Expenses | $208,000,000 | $208,000,000 | $179,457,000 | $204,678,000 |
| Investments And Advances | $57,000,000 | $135,000,000 | $199,901,000 | $148,970,000 |
| Available For Sale Securities | $57,000,000 | $135,000,000 | $199,901,000 | $148,970,000 |
| Goodwill | $44,000,000 | $44,000,000 | $44,406,000 | $44,406,000 |
| Net PPE | $244,000,000 | $266,000,000 | $290,566,000 | $259,726,000 |
| Accumulated Depreciation | $-136,000,000 | $-112,000,000 | $-83,401,000 | $-63,381,000 |
| Gross PPE | $380,000,000 | $378,000,000 | $373,967,000 | $323,107,000 |
| Leases | $55,000,000 | $58,000,000 | $58,683,000 | $43,941,000 |
| Other Properties | $103,000,000 | $99,000,000 | $94,694,000 | $50,885,000 |
| Machinery Furniture Equipment | $23,000,000 | $22,000,000 | $22,615,000 | $19,416,000 |
| Buildings And Improvements | $182,000,000 | $182,000,000 | $181,356,000 | $2,798,000 |
| Land And Improvements | $17,000,000 | $17,000,000 | $16,619,000 | $16,619,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $25,000,000 | $23,000,000 | $15,110,000 | $9,280,000 |
| Work In Process | $27,000,000 | $22,000,000 | $18,859,000 | $17,486,000 |
| Other Short Term Investments | $259,000,000 | $436,000,000 | $363,625,000 | $614,818,000 |
| Foreign Currency Translation Adjustments | - | $-1,650,000 | $-606,000 | $-845,000 |
| Unrealized Gain Loss | - | $1,007,000 | $1,253,000 | $-5,728,000 |
| Current Deferred Revenue | - | - | $0 | $1,479,000 |
| Construction In Progress | - | - | $867,000 | $189,448,000 |
| Non Current Deferred Revenue | - | - | - | $0 |
| Other Investments | - | - | - | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-487,000,000 | $-434,000,000 | $-522,000,000 | $-526,588,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-466,000,000 | $-414,000,000 | $-475,000,000 | $-380,465,000 |
| Cash Flow From Continuing Operating Activities | $-466,000,000 | $-414,000,000 | $-475,000,000 | $-380,465,000 |
| Investing Activities | ||||
| Capital Expenditure | $-21,000,000 | $-20,000,000 | $-47,000,000 | $-146,123,000 |
| Investing Cash Flow | $236,000,000 | $-18,000,000 | $168,000,000 | $-291,652,000 |
| Cash Flow From Continuing Investing Activities | $236,000,000 | $-18,000,000 | $168,000,000 | $-291,652,000 |
| Net Other Investing Changes | $-1,000,000 | $-2,000,000 | $-6,000,000 | $-844,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $86,000,000 | $392,000,000 | $387,000,000 | $0 |
| Financing Cash Flow | $478,000,000 | $399,000,000 | $388,000,000 | $501,208,000 |
| Cash Flow From Continuing Financing Activities | $478,000,000 | $399,000,000 | $388,000,000 | $501,208,000 |
| Net Other Financing Charges | $392,000,000 | $7,000,000 | $1,000,000 | $490,395,000 |
| Net Common Stock Issuance | $86,000,000 | $392,000,000 | $387,000,000 | $0 |
| Common Stock Issuance | $86,000,000 | $392,000,000 | $387,000,000 | $0 |
| Other | ||||
| End Cash Position | $436,000,000 | $184,000,000 | $219,000,000 | $137,601,000 |
| Beginning Cash Position | $184,000,000 | $219,000,000 | $138,000,000 | $309,585,000 |
| Effect Of Exchange Rate Changes | $4,000,000 | $-2,000,000 | $0 | $-1,075,000 |
| Changes In Cash | $248,000,000 | $-33,000,000 | $81,000,000 | $-170,909,000 |
| Net Investment Purchase And Sale | $258,000,000 | $4,000,000 | $221,000,000 | $-69,660,000 |
| Sale Of Investment | $444,000,000 | $413,000,000 | $747,000,000 | $545,075,000 |
| Purchase Of Investment | $-186,000,000 | $-409,000,000 | $-526,000,000 | $-614,735,000 |
| Net Intangibles Purchase And Sale | $-15,000,000 | $-13,000,000 | $-3,000,000 | $-30,000,000 |
| Purchase Of Intangibles | $-15,000,000 | $-13,000,000 | $-3,000,000 | $-30,000,000 |
| Net PPE Purchase And Sale | $-6,000,000 | $-7,000,000 | $-44,000,000 | $-116,123,000 |
| Purchase Of PPE | $-6,000,000 | $-7,000,000 | $-44,000,000 | $-116,123,000 |
| Change In Working Capital | $-23,000,000 | $14,000,000 | $-16,000,000 | $60,235,000 |
| Change In Payables And Accrued Expense | $24,000,000 | $47,000,000 | $-1,000,000 | $79,845,000 |
| Change In Payable | $24,000,000 | $47,000,000 | $-1,000,000 | $79,845,000 |
| Change In Account Payable | $24,000,000 | $47,000,000 | $-1,000,000 | $79,845,000 |
| Change In Prepaid Assets | $-10,000,000 | $12,000,000 | $15,000,000 | $3,798,000 |
| Change In Inventory | $-6,000,000 | $-11,000,000 | $-7,000,000 | $-9,701,000 |
| Change In Receivables | $-31,000,000 | $-34,000,000 | $-23,000,000 | $-12,068,000 |
| Changes In Account Receivables | $-31,000,000 | $-34,000,000 | $-23,000,000 | $-12,068,000 |
| Other Non Cash Items | $-52,000,000 | $-40,000,000 | $-1,060,000 | $96,126,000 |
| Stock Based Compensation | $153,000,000 | $158,000,000 | $135,000,000 | $130,377,000 |
| Amortization Of Securities | $-4,000,000 | $-13,000,000 | $-13,000,000 | $2,699,000 |
| Depreciation Amortization Depletion | $35,000,000 | $36,000,000 | $26,000,000 | $18,220,000 |
| Depreciation And Amortization | $35,000,000 | $36,000,000 | $26,000,000 | $18,220,000 |
| Net Income From Continuing Operations | $-575,000,000 | $-569,000,000 | $-607,000,000 | $-707,421,000 |
| Proceeds From Stock Option Exercised | - | $11,258,000 | $8,415,000 | $10,813,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-75,025,000 |
| Purchase Of Business | - | $0 | $0 | $-75,025,000 |
| Unrealized Gain Loss On Investment Securities | - | $1,115,000 | $-397,000 | $19,299,000 |
| Change In Other Working Capital | - | - | $-3,098,000 | $-1,639,000 |
Fetched: 2026-06-18